ArticleDigestive diseases and sciences2026
Prevalence and Costs of Non-esophageal Eosinophilic Gastrointestinal Diseases in the United States.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWhile the prevalence of eosinophilic esophagitis (EoE) has increased, estimates of prevalence trends for non-esophageal eosinophilic gastrointestinal disease (EGIDs) are limited and costs associated with these conditions are unknown.
aimsTo estimate prevalence and healthcare costs for non-esophageal EGIDs in the U.S.
methodsWe analyzed two national health insurance claims databases, MarketScan (2009-2022) and Medicare (2009-2017), to calculate annual prevalence and healthcare cost for patients with ≥ 1 ICD-9/10 code for eosinophilic gastritis or gastroenteritis (EoG/EGE) or eosinophilic colitis (EoC). Estimates were age and sex-standardized to the 2020 U.S. Census data. Inflation adjusted costs included inpatient, outpatient, and pharmaceutical claims for the latest study year.
resultsPrevalence rates were 5.49/100,000 and 11.47/100,000 for EoG/EGE, and 1.95/100,000 and 7.91/100,000 for EoC, in MarketScan and Medicare, respectively. While overall prevalence increased modestly, EoC prevalence increased 2.7-fold in Medicare. Standardized to the U.S. population, prevalence was 6.6/100,000 for EoG/EGE and 3.0/100,000 for EoC, equal to 21,733 EoG/EGE and 9,944 EoC cases. The total healthcare costs were $2.08 million in 2022 for MarketScan and $3.87 million in 2017 for Medicare, mostly attributed to outpatient procedures. Extrapolated national one-year costs adjusted for 2022 inflation totaled $114 million.
conclusionsFor all non-esophageal EGIDs combined, there was a modest increase in prevalence over the last decade, yet non-esophageal EGIDs remained rare. Notably, EoC demonstrated a nearly three-fold increase among Medicare beneficiaries. Consistent with this finding, costs and burden of disease are highest among Medicare enrollees, suggesting older patients have more complex non-esophageal EGID healthcare needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.